Content Library

Welcome to the content library for the HER2-Targeted Therapies Summit

If you have anything you would like us to share in the content library, please contact us at info@hansonwade.com

Exclusive SWOT Analysis of Enhertu (trastuzumab deruxtecan)

EXCLUSIVE SWOT ANALYSIS FROM:

Hanson Wade

Strength, Weakness, Opportunity and Threat Analysis of Enhertu (trastuzumab deruxtecan), a HER2-targeting antibody-drug conjugate (ADC) bearing a topoisomerase inhibitor payload; approved for unresectable or metastatic HER2-positive breast cancer patients.

 

Access the SWOT Analysis Here

Exclusive SWOT Analysis of Trodelvy (sacituzumab govitecan-hziy)

EXCLUSIVE SWOT ANALYSIS FROM:

Hanson Wade

Strength, Weakness, Opportunity and Threat Analysis of Trodelvy (sacituzumab govitecan-hziy), a Trop-2-directed antibody-drug conjugate (ADC) bearing a topoisomerase inhibitor payload; approved for patients with relapsed or refractory metastatic triple-negative breast cancer (TNBC).

 

Access the SWOT Analysis Here

Exclusive Interview

EXCLUSIVE INTERVIEW WITH:

Markus Zettl
Senior Director, Immuno Oncology
Pieris

"There is an emerging opportunity to use blood-based assessment of HER2 status and immunogenicity to complement and improve current diagnostics."

 

Access the Interview Here